Because POLO only included patients with the gBRCA1/2 mutations, there were a larger number of mPDAC patients who may benefit from olaparib, including those with germline mutations in other components of the HR system (PALB2, ATM), or with different positive biomarkers for homologous recombination deficiency (HRD). This evidence concerns the gene PALB2 and hyperinsulinemic hypoglycemia, familial, 4.